{"entity":{"id":"idrx","kind":"company","name":"IDRx","aka":["IDRx, Inc."],"tldr":"IDRx, a Boston company, developed IDRX-42, a pill aimed at the KIT gene changes that drive most gastrointestinal stromal tumours (GIST). GSK bought the company in 2025.","summary":"IDRx, Inc. was a Boston-based, clinical-stage company developing precision treatments for gastrointestinal stromal tumours. Its lead molecule, IDRX-42, is a highly selective KIT tyrosine kinase inhibitor being developed for first- and second-line treatment; GSK's announcement says about 80% of GIST cases are driven by KIT mutations and that IDRX-42 has shown activity against all key primary and secondary KIT mutations. GSK agreed on 13 January 2025 to buy IDRx for USD 1 billion upfront plus a possible USD 150 million regulatory milestone, and completed the acquisition on 24 February 2025.","asOf":"2026-11-03","links":[{"label":"GSK enters agreement to acquire IDRx (6-K, 13 January 2025)","url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495425000242/a0538t.htm"},{"label":"GSK completes acquisition of IDRx (6-K, 24 February 2025)","url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495425001815/a1769y.htm"}],"tags":[],"related":[],"cancers":["gist"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["kit"],"drugs":["idrx-42"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No website or founding year is recorded."],"hq":"Boston, MA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":1000000000,"source":"https://www.sec.gov/Archives/edgar/data/1131399/000165495425000242/a0538t.htm","note":"GSK's announcement of 13 January 2025, filed on a 6-K: USD 1 billion upfront with a potential additional USD 150 million success-based regulatory approval milestone; completion announced 24 February 2025"}],"acquiredBy":"gsk"},"route":"/companies/idrx/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"idrx-42","kind":"drug","name":"IDRX-42","route":"/drugs/idrx-42/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}